What are genomic sequencing, genetic testing, and biomarker testing
Understanding Genomic Sequencing, Genetic Testing, and Biomarker Testing
These are three related but distinct approaches to understanding cancer at the molecular level. Let me break down each one:
Genomic Sequencing
Genomic sequencing is the process of reading the complete genetic code (DNA) of cancer cells to identify mutations and changes. Think of it like reading an instruction manual letter-by-letter to find all the typos and errors.
What it does:
- Maps out thousands of genetic variations in tumor cells
- Identifies mutations that drive cancer growth
- Can reveal new mutations that might be targetable with specific drugs
- Provides a comprehensive "genetic fingerprint" of the cancer
Example: Sequencing might reveal that a lung cancer has a specific EGFR mutation, which tells doctors the cancer will likely respond to EGFR-targeted drugs.
Genetic Testing
Genetic testing typically refers to testing YOUR inherited DNA (not the cancer's DNA) to see if you carry mutations that increase cancer risk.
What it does:
- Checks for inherited gene mutations you were born with
- Identifies if you have higher lifetime cancer risk
- Helps determine if family members should be screened
- Informs prevention and surveillance strategies
Common examples:
- BRCA1/BRCA2 testing (breast and ovarian cancer risk)
- Lynch syndrome testing (colorectal cancer risk)
- PTEN testing (multiple cancer types)
Important distinction: This is about YOUR germline (inherited) DNA, not your tumor's DNA.
Biomarker Testing
Biomarkers are measurable characteristics of cancer cells that help predict how the cancer will behave and which treatments might work best. They're like "flags" that oncologists look for.
What it does:
- Identifies specific proteins, mutations, or other features in tumor cells
- Predicts treatment response and prognosis
- Guides treatment selection
- Can be detected through various tests (sequencing, immunohistochemistry, blood tests)
Common biomarkers include:
- Hormone receptors (ER/PR in breast cancer) - indicates if hormone therapy will work
- HER2 status - shows if targeted HER2 drugs are appropriate
- PD-L1 expression - predicts response to immunotherapy
- BRAF, KRAS, EGFR mutations - specific mutations that respond to targeted drugs
- Microsatellite instability (MSI) - indicates immunotherapy eligibility
- Tumor mutational burden (TMB) - predicts immunotherapy response
How They Work Together
According to NCCN Guidelines, modern cancer care often uses all three approaches:
- Genetic testing → Identifies if you have inherited risk factors
- Genomic sequencing → Reads your tumor's DNA to find mutations
- Biomarker testing → Identifies specific features that guide treatment selection
Real-world example: A patient with breast cancer might have:
- Genetic testing showing no BRCA mutations (low inherited risk)
- Genomic sequencing revealing an HER2 amplification in the tumor
- Biomarker testing confirming HER2-positive status
- Result: HER2-targeted therapy (like trastuzumab) becomes the treatment focus
Why This Matters for Your Care
The American Cancer Society and NCCN Guidelines recommend that most cancer patients have biomarker testing on their tumor to guide treatment decisions. This helps oncologists:
- Select the most effective drugs for YOUR specific cancer
- Avoid ineffective treatments
- Identify clinical trial opportunities
- Predict how well treatment might work
Questions to Ask Your Oncologist
If you're facing a cancer diagnosis, consider asking:
- "What biomarker testing has been done on my tumor, and what did it show?"
- "Are there any genetic tests I should have to understand my inherited cancer risk?"
- "Based on my biomarkers, what treatment options are most likely to work for me?"
- "Are there any additional genomic tests that would help guide my treatment?"
- "Will my insurance cover these tests?"
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Your next question, already answered
Tap to keep going. 2 free answers, then a free account.
Ask Navis about your case
That answer is general. Ask about your specific situation. Answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Sources & medical oversight
- Built by OpenCancer’s team of physician-scientists and cancer survivors.
- Last updated April 8, 2026. Informational only — not a substitute for your oncology team.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Related Services
Services that may help with diagnosis for cancer patients
Have your records handy? Add them to a private case for a deeper, personalized read →
More questions about General
- What is genomics England program
- What is next-generation sequencing (NGS) and should I get it for my cancer
- Has anyone had the genetic testing before chemotherapy that is called DYPD come back abnormal? Says that the chemo...
- How do I interpret my biomarker test results
- What is whole exome sequencing and when is it useful for cancer
- What somatic and germline testing is recommended for me
- What is minimal residual disease (MRD) testing
- What is circulating tumor DNA (ctDNA) testing